Colon Cancer Rates Drop in Older Americans, but Disparities Remain

Dramatic progress has been made in reducing colon cancer incidence and death rates in the U.S., but concerns remain about striking racial and socio-economic disparities, according to new national statistics on colorectal cancer.
Published Online: March 18, 2014
“Dramatic” progress has been made in reducing colon cancer incidence and death rates in the U.S., but concerns remain about “striking” racial and socio-economic disparities, according to new national statistics on colorectal cancer.

During the past decade, colon cancer incidence rates dropped by 30% in adults 50 and older, with the largest improvements seen in people older than age 65, the group most likely to die from the disease, found the report published Monday in CA: A Cancer Journal for Clinicians.

“We were very surprised to see that kind of drop in just one decade. That's enormous,” said Rebecca Siegel, director of surveillance information for the American Cancer Society, and a co-author of the report.

Typically, declines in cancer rates average 1% to 2% annually, Siegel said, but in the case of colon cancer it was closer to 4%, which the report attributes to widespread increases in colonoscopy screening over the years.

Read the full story here: http://bit.ly/1fW4P6D

Source: Modern Healthcare

Feature
Recommended Articles
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
Measure definitions to estimate the effects of cost sharing on adherence to medications prescribed together (ie, concurrent adherence) are lacking.
The study found that the geriatric population in the United States receives prescriptions for mental health drugs at more than twice the rate that younger adults do, but they present a lower rate of seeking psychiatric care.
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Proposed mergers of Aetna and Humana, and Anthem and Cigna, raise questions of whether consumers will continue to see competition in health insurance markets.